Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Clinical trial NCT06887088 · RECRUITING

Trial details

NCT number: NCT06887088
Sponsor: Grupo Español Multidisciplinar de Melanoma
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Melanoma BRAF V600E/K Mutated Melanoma and Brain Metastases

Start date: 2025-05-29
Primary completion: 2028-01-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.